Kura Oncology develops precision cancer medicines, with a focus on genetically defined blood cancers and solid tumors. Its best-known programs include menin inhibitors designed for acute myeloid leukemia (AML) and other cancers driven by specific genetic alterations such as NPM1 or KMT2A. The company partners and co-develops assets to advance late-stage clinical programs toward regulatory approval. Its customers, if products reach market, would be hematologists, oncologists and hospital systems treating genetically stratified patients.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 14.1 | — | -57.4 | — |
| Q2 2025 | 15.3 | — | -66.1 | — |
| Q3 2025 | 20.8 | — | -74.1 | — |
| Q4 2025 | 17.3 | — | -81 | — |
| Q1 2026 | 18.3 | 29.5% | -73.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: International General Insurance Holdings Ltd. (IGIC), Five Star Bancorp (FSBC), Mission Produce, Inc. (AVO), Lumexa Imaging Holdings, Inc. (LMRI), Versamet Royalties Corporation (VMET), Janux Therapeutics, Inc. (JANX)